Sodium glucose cotransporter 2 inhibitors are expected to ameliorate the abnormalities associated with metabolic syndrome including non-alcoholic fatty liver disease. In this study, we investigated the effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on the development of non-alcoholic fatty liver disease-related liver tumorigenesis in C57BL/KsJ-+Lepr db /+Lepr db obese and...

The non-alcoholic fatty liver disease is considered a predominant hepatopathy worldwide and a component of metabolic syndrome. It represents a risk factor for the development of cardiovascular diseases, independently of the presence of diabetes mellitus, hypertension and obesity. For this reason, nowadays an epidemiological analysis and a research of the causes that correlate non-alcoholic fatt...

The high prevalence of non-alcoholic fatty liver disease (NAFLD) has made the condition an important public health issue. Two clinical entities are manifestations of NAFLD, namely, non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). The former tends to be benign and non-progressive while the latter can progress to cirrhosis, which in rare cases gives rise to hepatocellula...

Objectives: This study aimed to investigate the effects of non-alcoholic fatty liver disease on thyroid nodule prevalence
 Methods: A total 384 patients who were followed up with Grade 2-3 Non-Alcoholic Fatty Liver diagnosis investigated for presence multinodular and/or nodular goiter. Demographic characteristics, biochemical data, and abdominal ultrasonography reports collected from patie...

Non-alcoholic fatty liver disease affects approximately one-third of the population worldwide, and its incidence continues to increase with the increasing prevalence of other metabolic disorders such as type 2 diabetes. As non-alcoholic fatty liver disease can progress to liver cirrhosis, its treatment is attracting greater attention. The pathogenesis of non-alcoholic fatty liver disease is clo...

Background: Even though alcoholic liver disease is common disease in India, there are only limited reports about insulin resistance and no reports about lipid bound sialic acid in these cases. The present study was designed to evaluate insulin resistance and lipid bound sialic acid levels in patients with alcoholic liver disease Materials and methods: 50 alcohol liver disease cases groups [Fatt...

"Erratum: Diagnostic and prognostic potential of kallistatin in assessment liver parenchyma changes patients with non-alcoholic fatty disease hypertension" published on 09 Nov 2021 by Akadémiai Kiadó.

conclusions it seems that hp eradication per se might not affect lfc, lft, lipid profile, and insulin resistance in dyspeptic nafld patients. results one hundred (49 males) patients with the mean age of 43.46 (± 11.52) were studied. repeated measure anova showed a significant reduction in lfc, anthropometric measurements, and laboratory parameters (except for hdl) in the both groups during the ...

In order to investigate the mechanism of the therapeutic effect of puerarin on non-alcoholic fatty liver disease, a non-alcoholic fatty disease male rat model was induced by a high fat diet, all rats were randomly divided into a blank group, model group, simavastatin group and puerarin group. After 4 weeks of drug treatment, the liver was slided to investigate pathological morphology. Elisa was...

Obesity and metabolic syndrome are healthcare problems that continue to rise in frequency worldwide. Both phenotypes are a strong predictor for development of liver steatosis in the context of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis. Ultrasound may detect steatosis, but its sensitivity is limited and liver biopsy is still considered to be the gold standard. Less invas...